01 / The Personal Catalyst
Stagnant Protocols & The Spark
Standard oncology clinical defaults have remained largely stagnant for half a century, relying heavily on maximum-tolerated dose (MTD) chemotherapy. This approach often inflicts systemic genotoxicity, permanently damages host immunity, and risks secondary malignancies.
"During an intensive 18-month pediatric oncology journey with my son, I witnessed unexpected tumor clearance following a common, transient viral infection. This singular event bypassed the standard toxic paradigm entirely, sparking a relentless, multi-year pursuit of the precise biological mechanisms underlying virotherapy and immunotherapy."
02 / The Cognitive Challenge
Overcoming the Clinical Data Bottleneck
The sheer speed and volume of modern medical literature creates an immense, multi-disciplinary blind spot. Crucial insights are compartmentalized—virologists, immunologists, oncologists, and metabolic researchers rarely operate outside their specialized silos.
Because standard clinical workflows cannot scale to synthesize thousands of new, cross-disciplinary trial insights manually, promising combination treatments are routinely overlooked. The bottleneck is no longer a lack of raw data; it is the human computational limit of our translation pipeline.
03 / The Engineering Solution
Engineering the "No-Escape" Blueprint
OncoFi bridges this profound gap by applying technical software logic to complex biology. Drawing on my tenure as a software architect and executive, we have spent three years engineering a dedicated Protocol Engine.
Our solution dynamically queries over 30,000 clinical trials to construct omni-modal synergies. By algorithmically pairing physical agents—such as targeting a tumor's oxygenated perimeter with an oncolytic virus while colonizing its hypoxic core with therapeutic bacteria—the engine traps cancer cells in an evolutionary dead-end with zero escape routes.
Ultimately, in multi-million-dollar clinical studies and individual therapeutic plans alike, catching an overlooked biological variable does not just save R&D capital—it buys vital time for patients who have none to spare.